Regnum Corp. (RGMP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 1.55 Million USD | 2.98% |
| 2021 | 1.51 Million USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 1.56 Million USD | 0.71% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q4 | 1.55 Million USD | 0.73% |
| 2022 FY | 1.55 Million USD | 2.98% |
| 2022 Q2 | 1.53 Million USD | 0.74% |
| 2022 Q1 | 1.52 Million USD | 0.73% |
| 2022 Q3 | 1.54 Million USD | 0.74% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q4 | 1.51 Million USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 FY | 1.51 Million USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 96.225% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 62.264% |
| SQZ Biotechnologies Company | 27.47 Million USD | 94.338% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 96.414% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 94.775% |
| Mesoblast Limited | 118.7 Million USD | 98.69% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -64.033% |
| Genus plc | 233.1 Million USD | 99.333% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 46.919% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -15.771% |
| Marizyme, Inc. | 18.71 Million USD | 91.69% |
| ContraFect Corporation | 2.88 Million USD | 46.009% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -107.397% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1048.065% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -7.547% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 33.125% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 72.51% |
| MultiCell Technologies, Inc. | 202.58 USD | -767734.436% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 97.294% |
| EV Biologics, Inc. | 1.49 Million USD | -4.063% |
| Q BioMed Inc. | 4.1 Million USD | 62.154% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 95.301% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -146.871% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -26.63% |
| Biomind Labs Inc. | 735.54 Thousand USD | -111.474% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.093% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 88.032% |
| Skye Bioscience, Inc. | 4.61 Million USD | 66.297% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -75.154% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -999.139% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 73.506% |
| IMV Inc. | 28.88 Million USD | 94.615% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -5947.976% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 31.124% |
| GB Sciences, Inc. | 1.75 Million USD | 11.586% |
| Alpha Cognition Inc. | 1.22 Million USD | -27.459% |
| HST Global, Inc. | 98.31 Thousand USD | -1482.074% |
| CSL Limited | 12.18 Billion USD | 99.987% |
| Halberd Corporation | 150 Thousand USD | -936.986% |
| Enzolytics Inc. | 996.33 Thousand USD | -56.12% |
| Resverlogix Corp. | 6.49 Million USD | 76.036% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -225.755% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -508.579% |
| argenx SE | 20 Million USD | 92.223% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 96.586% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 42.575% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -15112.509% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.628% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -675.351% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 35.127% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -578.386% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 97.7% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 48.599% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -332.426% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 92.348% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -946.375% |
| BioStem Technologies, Inc. | 4.71 Million USD | 66.985% |
| ONE Bio Corp. | 19.71 Million USD | 92.11% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -521.739% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -525.394% |
| Agentix Corp. | 50 Thousand USD | -3010.958% |
| LadRx Corporation | 33.6 Thousand USD | -4528.575% |
| Cell Source, Inc. | 9.25 Million USD | 83.192% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -105.696% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -105.696% |
| NovAccess Global Inc. | 2.19 Million USD | 29.293% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 78.008% |
| Itoco Inc. | 228.37 Thousand USD | -581.101% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -637.281% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 68.784% |
| Kadimastem Ltd | 891.22 Thousand USD | -74.532% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -287.08% |
| CytoDyn Inc. | 30.07 Million USD | 94.828% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -221.191% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -342.09% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 80.109% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1169.779% |
| Rebus Holdings, Inc. | 310 Thousand USD | -401.767% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 67.151% |
| International Stem Cell Corporation | 4.17 Million USD | 62.77% |
| Bioxytran, Inc. | 1.92 Million USD | 19.196% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2392.236% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 28.677% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 81.295% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 81.881% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -480.403% |
| Neutra Corp. | 54.15 Thousand USD | -2772.219% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 15.001% |
| PureTech Health plc | 25.51 Million USD | 93.903% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -27.058% |
| IXICO plc | 472.02 Thousand USD | -229.535% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 89.965% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 97.502% |
| CSL Limited | 12.18 Billion USD | 99.987% |
| Cellectis S.A. | 92.77 Million USD | 98.323% |